Abstract

Trivalent adjuvanted inactivated influenza vaccine (aIIV3) and trivalent high-dose inactivated influenza vaccine (HD-IIV3) are US-licensed for adults aged 65 years and older. Data are needed on the comparative safety, reactogenicity, and health-related quality of life (HRQOL) effects of these vaccines. To compare safety, reactogenicity, and changes in HRQOL scores after aIIV3 vs HD-IIV3. This randomized blinded clinical trial was a multicenter US study conducted during the 2017 to 2018 and 2018 to 2019 influenza seasons. Among 778 community-dwelling adults aged at least 65 years and assessed for eligibility, 13 were ineligible and 8 withdrew before randomization. Statistical analysis was performed from August 2019 to August 2020. Intramuscular administration of aIIV3 or HD-IIV3 after age-stratification (65-79 years; ≥80 years) and randomization. Proportions of participants with moderate-to-severe injection-site pain and 14 other solicited reactions during days 1 to 8, using a noninferiority test (5% noninferiority margin), and serious adverse events (SAE) and adverse events of clinical interest (AECI), including new-onset immune-mediated conditions, during days 1 to 43. Changes in HRQOL scores before and after vaccination (days 1, 3) were also compared between study groups. A total of 757 adults were randomized, 378 to receive aIIV3 and 379 to receive HD-IIV3. Of these participants, there were 420 women (55%) and 589 White individuals (78%) with a median (range) age of 72 (65-97) years. The proportion reporting moderate-to-severe injection-site pain, limiting or preventing activity, after aIIV3 (12 participants [3.2%]) (primary outcome) was noninferior compared with HD-IIV3 (22 participants [5.8%]) (difference -2.7%; 95% CI, -5.8 to 0.4). Ten reactions met noninferiority criteria for aIIV3; 4 (moderate-to-severe injection-site tenderness, arthralgia, fatigue, malaise) did not. It was inconclusive whether these 4 reactions occurred in higher proportions of participants after aIIV3. No participant sought medical care for a vaccine reaction. No AECI was observed. Nine participants had at least SAE after aIIV3 (2.4%; 95% CI,1.1% to 4.5%); 3 had at least 1 SAE after HD-IIV3 (0.8%; 95% CI, 0.2% to 2.2%). No SAE was associated with vaccination. Changes in prevaccination and postvaccination HRQOL scores were not clinically meaningful and not different between the groups. Overall safety and HRQOL findings were similar after aIIV3 and HD-IIV3, and consistent with prelicensure data. From a safety standpoint, this study's results support using either vaccine to prevent influenza in older adults. ClinicalTrials.gov Identifier: NCT03183908.

Highlights

  • Older adults are at high risk for severe influenza illness, cardiovascular events, hospitalization, functional decline, and death following influenza infection.[1,2,3,4,5,6,7,8,9,10] Hospitalization rates for laboratory confirmed influenza are up to 10 times higher in people aged 65 years or older compared with younger adults.[1]

  • The proportion reporting moderate-to-severe injection-site pain, limiting or preventing activity, after trivalent adjuvanted inactivated influenza vaccine (aIIV3) (12 participants [3.2%]) was noninferior compared with trivalent high-dose inactivated influenza (HD-IIV3) (22 participants [5.8%])

  • Nine participants had at least serious adverse events (SAE) after aIIV3 (2.4%; 95% CI,1.1% to 4.5%); 3 had at least 1 SAE after HD-IIV3 (0.8%; 95% CI, 0.2% to 2.2%)

Read more

Summary

Introduction

Older adults are at high risk for severe influenza illness, cardiovascular events, hospitalization, functional decline, and death following influenza infection.[1,2,3,4,5,6,7,8,9,10] Hospitalization rates for laboratory confirmed influenza are up to 10 times higher in people aged 65 years or older compared with younger adults.[1]. In addition to these age-specific vaccines, quadrivalent standard-dose, unadjuvanted inactivated influenza vaccines (SD-IIV4) and quadrivalent recombinant influenza vaccine (RIV4) are licensed and recommended for people aged 65 years and older.[11]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call